Adial Pharmaceuticals (ADIL)
Develops precision-oriented therapies for ulcerative colitis and genetically selected alcohol use disorder patients.
Something off on this page? Send us feedback.
Develops two unapproved precision-oriented drug programs: colon-targeted AT177 for ulcerative colitis and genetically guided AD04 for alcohol use disorder. The business operates with a small internal team and relies on outside providers for development and supply.
Develops two unapproved, precision-oriented drug programs: AT177, an oral colon-targeted prodrug intended for ulcerative colitis, and AD04, a very-low-dose ondansetron treatment paired with a genetic companion test for selected patients with alcohol use disorder. AT177 became the lead program through the acquisition of Azora Therapeutics and remains preclinical; AD04 requires additional pivotal work.
Operates from Virginia with a small internal team, using outside research, manufacturing and clinical-trial providers. Immediate AT177 development is U.S.-oriented, with U.S.-based GMP manufacturing planned, while AD04 development is primarily U.S.-focused and has a proposed, non-definitive European commercialization framework.
Neither program is approved, and the company has no product revenue or internal sales, marketing, or distribution capability. AD04's proposed use depends on both drug approval and an acceptable regulatory path for its companion diagnostic; development and supply depend on CROs, manufacturers and other contractors.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| Aug 3, 2026 | Alliance Global Partners | Initiate | Buy | ||
| Aug 3, 2026 | Industrial Alliance Securities | Target | $11 | ||
| Jun 15, 2026 | Loop Capital Markets | Target | $6 | ||
| Feb 11, 2026 | UBS | Target | $8 | ||
| Sep 30, 2025 | Maxim Group | Upgrade | Hold | Buy |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $28.7M · Total debt $0 · Total assets $29.1M · Shareholders' equity $156.0K
- Revenue
- $0
- Operating income
- −$52.0M
- Net income
- −$52.0M
No dividends on record.
| Institutions15 holders · as of Mar 31, 2026 | 1.36% | 35.6K shares | |
| Insiders6 holders · as of Jun 16, 2026 | 15.37% | 403.6K shares | |
| Strategic holders1 holder · as of Jul 16, 2026 | 14.79% | 388.3K shares | |
| Otherremainder | 68.48% | 1.80M shares |
2.63M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (2.63M in the company's Sep 3, 2026 report, 959.6K elsewhere); stakes use the report.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Coastlands Capital LPStrategic10 percent owner | 14.79% | 388,308 | Form 4filed Jul 16, 2026 ↗ |
Matt DavidsonInsiderdirector, officer: Chief Development Officer | 11.46% | 300,918 | Form 4filed Jun 16, 2026 ↗ |
Cary J. ClaiborneInsiderdirector, officer: Chief Executive Officer | 1.54% | 40,417 | Form 4filed Apr 9, 2026 ↗ |
Tony GoodmanInsiderdirector, officer: Chief Operating Officer | 1.01% | 26,523 | Form 4filed Apr 9, 2026 ↗ |
Geode Capital Management, LLCInstitution | 0.92% | 24,249 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 14, 2026 | Coastlands Capital LP | 10 percent owner | +2,000 | $2.65 |
| Jul 16, 2026 | Coastlands Capital LP | 10 percent owner | +1,233 | $2.75 |
| Jul 9, 2026 | Coastlands Capital LP | 10 percent owner | +10,053 | $2.79 |
| Jul 10, 2026 | Coastlands Capital LP | 10 percent owner | +1,700 | $2.70 |
| Jun 29, 2026 | Coastlands Capital LP | 10 percent owner | +25,000 | $2.60 |
- Abivax (ADR)
Later-stage oral UC benchmark with obefazimod.
- Equillium
Closest oral AhR-modulation challenger in UC.
- Alkermes
Monthly naltrexone alternative in alcohol dependence.
- AbbVie
Broad marketed UC franchise in JAK and IL-23 therapy.
- Takeda (ADR)
Gut-selective biologic franchise in moderate-to-severe UC.
- Indivior
AUD pipeline and addiction franchise overlap.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Adial Pharmaceuticals | $6.17 | −3.59% | $6.1M | — | — | — | — |
| Abivax (ADR) | $112.35 | +0.99% | $8.16B | — | — | — | — |
| Equillium | $2.05 | −9.29% | $142.3M | — | — | — | — |
| Alkermes | $47.74 | +1.14% | $8.01B | 124.6 | — | 4.8 | +27.0% |
| AbbVie | $261.54 | −0.06% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Takeda (ADR) | $18.51 | +0.38% | $58.65B | 51.2 | 56.7 | 2.0 | +5.8% |
| Indivior | $35.05 | −0.03% | $4.37B | 12.6 | 7.8 | 3.3 | +13.6% |
| Median | 62.5 | 17.2 | 4.0 | +11.9% |